Literature DB >> 24441661

Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases.

Kruti P Maniar1, Yihong Wang, Kala Visvanathan, Ie-Ming Shih, Robert J Kurman.   

Abstract

Most of the literature on serous borderline/atypical proliferative serous tumors (SBT/APSTs) shows no effect of microinvasion or lymph node involvement on outcome. This study is a morphologic and immunohistochemical analysis of the cells comprising SBT/APSTs, microinvasion, lymph node involvement, and low-grade serous carcinoma (LGSC) in an attempt to explain this unusual behavior. We found that the cells in microinvasion and in lymph nodes were morphologically similar to the cells in SBT/APSTs but differed significantly from the cells in LGSCs. In addition, one particular population of cells, those with abundant eosinophilic cytoplasm (eosinophilic cells), in SBT/APSTs, microinvasion, and lymph nodes showed a significant loss of expression of ER, PR, and WT-1 compared with the cuboidal/columnar tumor cells, both in cases of microinvasion (P<0.001 for all 3 markers) and lymph node involvement (P<0.001, P=0.02, P=0.002, respectively). There was a significant decrease in the Ki-67 proliferation index for microinvasion (P=0.004) and a decreasing trend for lymph node involvement (nonsignificant) compared with the columnar/cuboidal cells. In addition, cells in these tumors showed morphologic evidence of apoptosis, which was confirmed by immunostaining with M30, a marker of apoptosis. In contrast, LGSCs lacked eosinophilic cells and showed no loss of expression of ER, PR, and WT-1. They also had a significantly higher Ki-67 proliferation index than their associated SBT/APSTs (P=0.029). On the basis of these findings, we propose that the cells comprising microinvasion do not represent an invasive neoplastic process. Instead, in view of the loss of expression of ER, PR, and WT-1, evidence of apoptosis, and decrease in the Ki-67 proliferation index, we postulate that they are senescent and terminally differentiated with a subset of cells undergoing apoptosis, which could explain their lack of an adverse effect on outcome.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24441661      PMCID: PMC4020949          DOI: 10.1097/PAS.0000000000000155

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  32 in total

1.  Ovarian serous borderline epithelial tumors with multiple retroperitoneal nodal involvement: metastasis or malignant transformation of epithelial glandular inclusions?

Authors:  M Shiraki; C N Otis; J T Donovan; J L Powell
Journal:  Gynecol Oncol       Date:  1992-08       Impact factor: 5.482

2.  Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer.

Authors:  W Remmele; U Hildebrand; H A Hienz; P J Klein; M Vierbuchen; L J Behnken; B Heicke; E Scheidt
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

3.  Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases.

Authors:  D A Bell; R E Scully
Journal:  Hum Pathol       Date:  1990-04       Impact factor: 3.466

4.  Serous tumor of low malignant potential with early stromal invasion (serous LMP with microinvasion).

Authors:  F A Tavassoli
Journal:  Mod Pathol       Date:  1988-11       Impact factor: 7.842

5.  Epithelial ovarian tumors of borderline malignancy: long-term follow-up.

Authors:  A C Casey; D A Bell; J M Lage; A F Fuller; N Nikrui; L W Rice
Journal:  Gynecol Oncol       Date:  1993-09       Impact factor: 5.482

6.  Possible metaplastic origin of lymph node "metastases" in serous ovarian tumor of low malignant potential (borderline serous tumor).

Authors:  N Kadar; M Krumerman
Journal:  Gynecol Oncol       Date:  1995-12       Impact factor: 5.482

7.  Proliferative serous tumors of the ovary. Histologic features and prognosis.

Authors:  A L Katzenstein; M T Mazur; T E Morgan; M S Kao
Journal:  Am J Surg Pathol       Date:  1978-12       Impact factor: 6.394

8.  Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential.

Authors:  J F Leake; J S Rader; J D Woodruff; N B Rosenshein
Journal:  Gynecol Oncol       Date:  1991-08       Impact factor: 5.482

Review 9.  Ovarian serous borderline tumors with lymph node involvement. Clinicopathologic and DNA content study of seven cases and review of the literature.

Authors:  L K Tan; S D Flynn; M L Carcangiu
Journal:  Am J Surg Pathol       Date:  1994-09       Impact factor: 6.394

10.  Borderline and malignant serous tumor arising in pelvic lymph nodes: evidence of origin in benign glandular inclusions.

Authors:  M Prade; A Spatz; R Bentley; P Duvillard; C Bognel; S J Robboy
Journal:  Int J Gynecol Pathol       Date:  1995-01       Impact factor: 2.762

View more
  10 in total

Review 1.  A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.

Authors:  Robert A Soslow; Rajmohan Murali
Journal:  Semin Diagn Pathol       Date:  2017-11-20       Impact factor: 3.464

2.  Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.

Authors:  Russell Vang; Charlotte G Hannibal; Jette Junge; Kirsten Frederiksen; Susanne K Kjaer; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2017-06       Impact factor: 6.394

3.  BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.

Authors:  Felix Zeppernick; Laura Ardighieri; Charlotte G Hannibal; Russell Vang; Jette Junge; Susanne K Kjaer; Rugang Zhang; Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2014-12       Impact factor: 6.394

Review 4.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2016-04       Impact factor: 4.307

5.  Pathologic Classification of Ovarian Cancer.

Authors:  Stephanie M McGregor
Journal:  Methods Mol Biol       Date:  2022

6.  BRAFV600E mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary.

Authors:  Gulisa Turashvili; Rachel N Grisham; Sarah Chiang; Deborah F DeLair; Kay J Park; Robert A Soslow; Rajmohan Murali
Journal:  Histopathology       Date:  2018-06-22       Impact factor: 5.087

Review 7.  Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.

Authors:  Steffen Hauptmann; Katrin Friedrich; Raymond Redline; Stefanie Avril
Journal:  Virchows Arch       Date:  2016-12-27       Impact factor: 4.064

Review 8.  The Many Faces of Serous Neoplasms and Related Lesions of the Female Pelvis: A Review.

Authors:  Sameera Rashid; Maria A Arafah; Mohammed Akhtar
Journal:  Adv Anat Pathol       Date:  2022-05-01       Impact factor: 3.875

9.  Carbonic anhydrase XII as biomarker and therapeutic target in ovarian carcinomas.

Authors:  Lisa Hiepp; Doris Mayr; Kathrin Gärtner; Elisa Schmoeckel; Frederick Klauschen; Alexander Burges; Sven Mahner; Reinhard Zeidler; Bastian Czogalla
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

10.  High-grade ovarian cancer associated H/ACA snoRNAs promote cancer cell proliferation and survival.

Authors:  Laurence Faucher-Giguère; Audrey Roy; Gabrielle Deschamps-Francoeur; Sonia Couture; Ryan M Nottingham; Alan M Lambowitz; Michelle S Scott; Sherif Abou Elela
Journal:  NAR Cancer       Date:  2022-01-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.